• Login
    View Item 
    •   UCUDIR Home
    • Research Papers and Publications
    • UCU School of Medicine
    • View Item
    •   UCUDIR Home
    • Research Papers and Publications
    • UCU School of Medicine
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Factors Associated with Virological Non suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda

    Thumbnail
    View/Open
    The final, definitive version of this paper has been published in BMC Infectious Diseases Vol. 17 No. 326 (2017). All rights reserved. (370.9Kb)
    Date
    2017
    Author
    Bulage, Lilian
    Ssewanyana, Isaac
    Nankabirwa, Victoria
    Nsubuga, Fred
    Kihembo, Christine
    Pande, Gerald
    Ario, Alex R.
    Matovu, Joseph K. B.
    Wanyenze, Rhoda K.
    Kiyaga, Charles
    Metadata
    Show full item record
    Abstract
    Background: Despite the growing number of people on antiretroviral therapy (ART), there is limited information about virological non-suppression and its determinants among HIV-positive (HIV+) individuals enrolled in HIV care in many resource-limited settings. We estimated the proportion of virologically non-suppressed patients, and identified the factors associated with virological non-suppression. Methods: We conducted a descriptive cross-sectional study using routinely collected program data from viral load (VL) samples collected across the country for testing at the Central Public Health Laboratories (CPHL) in Uganda. Data were generated between August 2014 and July 2015. We extracted data on socio-demographic, clinical and VL testing results. We defined virological non-suppression as having ≥1000 copies of viral RNA/ml of blood for plasma or ≥5000 copies of viral RNA/ml of blood for dry blood spots. We used logistic regression to identify factors associated with virological non-suppression. Results: The study was composed of 100,678 patients; of these, 94,766(94%) were for routine monitoring, 3492(4%) were suspected treatment failures while 1436(1%) were repeat testers after suspected failure. The overall proportion of non-suppression was 11%. Patients on routine monitoring registered the lowest (10%) proportion of non-suppressed patients. Virological non-suppression was higher among suspected treatment failures (29%) and repeat testers after suspected failure (50%). Repeat testers after suspected failure were six times more likely to have Virological non-suppression (ORadj = 6.3, 95%CI = 5.5–7.2) when compared with suspected treatment failures (ORadj = 3.3, 95%CI = 3.0–3.6). The odds of virological non-suppression decreased with increasing age, with children aged 0–4 years (ORadj = 5.3, 95%CI = 4.6–6.1) and young adolescents (ORadj = 4.1, 95%CI = 3.7–4.6) registering the highest odds. Poor adherence (ORadj = 3.4, 95%CI = 2.9–3.9) and having active TB (ORadj = 1.9, 95%CI = 1.6–2.4) increased the odds of virological non-suppression. However, being on second/third line regimens (ORadj = 0.86, 95%CI = 0.78–0.95) protected patients against Virological non-suppression. Conclusion: Young age, poor adherence and having active TB increased the odds of Virological non-suppression while second/third line ART regimens were protective against non-suppression. We recommend close follow up and intensified targeted adherence support for repeat testers after suspected failure, children and adolescents.
    Use this URI to cite this item:
    https://hdl.handle.net/20.500.11951/283
    Collections
    • UCU School of Medicine [158]

    UCUDIR copyright © 2017-2019  UCU Library |  Search Library Catalogue
    Contact Us | Send Feedback
     
    Atmire NV
     

     

    Browse

    All of UCUDIRCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    UCUDIR copyright © 2017-2019  UCU Library |  Search Library Catalogue
    Contact Us | Send Feedback
     
    Atmire NV